Litigation Details for PAR PHARMACEUTICAL, INC. v. AMNEAL EU, LIMITED (D.N.J. 2020)
✉ Email this page to a colleague
PAR PHARMACEUTICAL, INC. v. AMNEAL EU, LIMITED (D.N.J. 2020)
| Docket | ⤷ Try a Trial | Date Filed | 2020-12-06 |
| Court | District Court, D. New Jersey | Date Terminated | 2022-02-09 |
| Cause | 35:271 Patent Infringement | Assigned To | Zahid Nisar Quraishi |
| Jury Demand | None | Referred To | Douglas Arpert |
| Parties | AMNEAL EU, LIMITED | ||
| Patents | 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785; 9,937,223 | ||
| Attorneys | ROBERT D. RHOAD | ||
| Firms | Stone Conroy LLC | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in PAR PHARMACEUTICAL, INC. v. AMNEAL EU, LIMITED
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for PAR PHARMACEUTICAL, INC. v. AMNEAL EU, LIMITED (D.N.J. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-03-16 | 12 | Redacted Document | maintaining a separate patent infringement action, based on U.S. Patents 9,744,209 and 9,750,785, against…. 2003)). The asserted patent, U.S. Patent No. 10,844,435 (“the ’435 patent”), claims a method for treating…2021. Par has also filed a patent infringement case, based on U.S. Patent 10,844,435 at issue here, against… for a drug claimed in a patent or the use of which was claimed in a patent; and 3) the purpose of the…[’435 patent], because [Amneal is] not seeking FDA approval for the uses claimed in the patent[] and | External link to document |
| 2021-03-30 | 14 | Exhibit B | Jul. 3 , 2020. ( Year : 2003 ) . 9,375,478 B1 6/2016 Kenney et al. … United States Patent ( 10) Patent No .: US 10,920,278…those skilled in the art. All publications , patents and patent physician. In certain aspects , the target… (45 ) Date of Patent : Feb. 16 , 2021 ( 54 ) METHOD TO TREAT HYPOTENSION…this 46-52 . patent is extended or adjusted under 35 | External link to document |
| 2021-05-03 | 22 | Redacted Document | maintaining a separate patent infringement action, based on U.S. Patents 9,744,209 and 9,750,785, against…, Ex. A (’435 Patent), claim 1.) Second, U.S. Patent No. 10,920, 278 (“the ’278 patent”), which claims…specific maximum doses. First, U.S. Patent No. 10,844,435 (“the ’435 patent”), which claims a method for …2021. Par has also filed a patent infringement case, based on U.S. Patent 10,844,435 at issue here, against…of the asserted ’278 patent, set forth below, mirrors claim 1 of the ’435 patent except the method is | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
